Skip to main content
Erschienen in: International Journal of Clinical Pharmacy 6/2018

Open Access 01.12.2018 | Research Article

Knowledge of cardiovascular disease risk factors and practice of primary prevention of cardiovascular disease by Community Pharmacists in Nigeria: a cross-sectional study

verfasst von: Casmir E. Amadi, Folasade O. Lawal, Amam C. Mbakwem, Jayne N. Ajuluchukwu, David A. Oke

Erschienen in: International Journal of Clinical Pharmacy | Ausgabe 6/2018

Abstract

Background Studies in international literature have shown that Community Pharmacists can make considerable impact in controlling cardiovascular disease risk factors, especially hypertension. In Nigeria, there are no studies on the knowledge of CVD risk factors by Community Pharmacists and their practice of primary prevention. Objective To assess the knowledge of CVD risk factors and practice of primary prevention of CVD amongst Nigerian community pharmacists. Setting Community Pharmacists in Lagos, Nigeria. Methods This cross-sectional study involved 168 Community Pharmacists. Their knowledge of CVD risk factors was assessed with the Heart Disease Fact Questionnaire. Their opportunistic screening practices for CVD risk factors (primary prevention) were also assessed. Main outcome measures Knowledge of CVD risk factors and practice of primary CVD prevention. Results The mean age of the participating pharmacists was 41.7 (± 11.2) years and 87 (51.8%) of them were males. The median number of years of practice was 9.0 (3–15) years. Mean knowledge score was 22.1 (± 3.0) with 154 (91.7%) of the subjects scoring above 70%. An average of 95.5% of the participants correctly identified hypertension, smoking, dyslipidaemia, obesity, physical inactivity and diabetes as CVD risk factors. Eighty-one (48.2%) had good practice of primary CVD prevention. Conclusion: This study shows that Community Pharmacists in Nigeria have very good knowledge level of CVD risk factors and almost 50% of them practised primary prevention of CVD.
Hinweise
The original version of this article was revised: Due to open choice cancellation.
A correction to this article is available online at https://​doi.​org/​10.​1007/​s11096-019-00903-6.

Impacts on practice

  • Because the Nigerian pharmacists in Nigeria have a very good knowledge of cardiovascular risk factors and have the skills to practice primary prevention, it is possible to organise a pharmacists-led mass-screening for cardiovascular disease in Nigeria.
  • Continuous training and support in knowledge of cardiovascular disease and prevention practice must be essential components of any government policy that seeks to improve the effectiveness of the primary prevention of CVD in Nigeria.

Introduction

Cardiovascular disease (CVD) is a pre-eminent but preventable cause of death globally, accounting for an estimated 29% of all deaths [1]. The relative contribution of CVD to the burden of disease remains high in low, middle and high income countries of the world [1]. Interestingly over 80% of the global burden of CVD is borne by the Low and Middle Income Countries (LMICs) in the face of their traditional high prevalence of infectious diseases and poverty-related morbidities and mortalities, constituting a double burden of disease profile [2, 3]. The rising prevalence of CVD in these LMICs is driven by rapid urbanization and its corollary of westernization of lifestyles viz increased consumption of saturated fats and sugars, high salt intake, increasing physical inactivity, smoking and unhealthy use of alcohol [4]. These risky behaviours predispose to the development of the metabolic risk factors for CVD such as obesity, hypertension, diabetes and dyslipidaemia [5]. In Nigeria CVD risk factors are highly prevalent. A recent meta-analysis showed that about 28.9% of adult Nigerians are hypertensive [6]. Similarly, the prevalence of diabetes is between 5 and 10% [7, 8] and dyslipidaemia 60.5% [9]. Prevalence of obesity, smoking and sedentary living is on the increase also [911]. Research data provides evidence that there is a rising trend of CVD events and death across Nigeria [12, 13].
Cardiovascular disease is preventable through effective control and management of its risk factors. Data from researches provide sufficient evidence to suggest that the primary prevention of CVD represents a cost-effective approach to reducing this burden [14].
Because patients have difficulties accessing primary-care physicians and health-care costs are rapidly rising, greater use of community-based models of care has been proposed [15]. Among these models is the greater integration of the pharmacist as a provider of health services and member of the health-care team. Community pharmacists are highly accessible health-care professionals in most communities and have demonstrated an effective role in the management of several of these risk factors [1618]. Their expertise in medicines management, adherence screening and management, and a growing role in health promotion has resulted in several studies demonstrating effective pharmacist involvement with multiple CVD risk factor management [19, 20].
With rising prevalence of CVD risk factors and CVD events and on a background of rising healthcare cost in Nigeria, Community Pharmacists may indeed have a role in stemming this tide. They, being community dwelling, are usually the first point of call for patients and appear more accessible and affordable to them. However, there is dearth of data on the knowledge and practice of primary prevention of CVD by this group of healthcare professionals in Nigeria.

Aim of the study

This study was designed to assess the knowledge of CVD risk factors and practice of primary prevention of CVD by Community Pharmacists in Lagos, Nigeria.

Ethics approval

Ethics approval for the study was obtained from the Health Research Ethics Committee of the Lagos University Teaching Hospital, Nigeria.

Methods

This was a cross sectional study. There were 800 registered Community Pharmacists in Lagos at the time of this study and they met monthly in twenty-two zones in the three senatorial districts of Lagos under the aegis of Lagos State Association of Community Pharmacists. Six zones (two from each of the three senatorial districts) were randomly selected for this study. The selection was based on the population density of the zones.
A sample size of 157 was calculated with the formula used when the survey population is less than 10,000 [21]. Allowing for an attrition rate of 20% the final sample size was 190. The leadership of the Association was approached for permission to carry out the study on their members. Their members were invited to participate in the study through a letter written by the researcher. The letter was read out to them by the Secretary of the Association in the plenary session of one of their monthly meetings, explaining the rationale for the study. To further enhance participation rate a copy of this letter was also pasted on the Association’s Notice Boards in the six zones selected for the members to read. We aimed at recruiting 32 pharmacists from each of the six zones. One hundred and ninety pharmacists agreed to participate in the study but only 168 completed and returned their questionnaire giving a response rate of 88.4%. Trained research personnel were used to administer a pretested, structured self-administered questionnaire to the consenting pharmacists during their monthly zonal meetings. Completing the questionnaire took an average of 20 min. The entire period of the study lasted for 12 weeks. The questionnaire was initially pretested among a group of twenty Community Pharmacists in Lagos. Their responses were used to fine tune the final version used for the study.
The questionnaire consisted of four sections. Section one comprised the socio-demographic information of the participants while section two assessed their knowledge of CVD risk factors using the widely validated Heart Disease Fact Questionnaire (HDFQ). The HDFQ is a 25-item measure of heart disease knowledge which evaluates of knowledge of risk factors for heart disease, the link between diabetes and heart disease and how to reduce the risk of heart disease in the diabetic population [22, 23]. It has been used in other populations with reliable test–retest reliability, internal consistency and satisfactory discriminant validity [22] and has also been used among staff members of a university in Nigeria in 2015 [24]. Responses were ‘True’, ‘false’ or ‘I don’t know’. Scores were summed up and total score greater than 20 indicated good knowledge. Scores were also expressed in percentages. Score of < 50% was classified as low level of knowledge, between 50 and 69% as moderate level of knowledge and HDFQ score > 70% as good level of knowledge. Questions that less than 70% of the respondents answered correctly were deemed unsatisfactory. Section three assessed the participants’ knowledge of the diagnostic cut-offs for hypertension, diabetes, dyslipidaemia and obesity while section four assessed their practice of primary prevention of CVD and comprised seven questions viz availability of functional sphygmomanometers, glucometers, routine measurement of blood pressure for their clients, routine measurement of BMI/waist circumference, awareness of any guidelines on hypertension, how frequently they advised their hypertensive and diabetic clients to check their cholesterol profile and how frequently they counselled their clients on healthy lifestyle choices in their Practices. Each of these questions was scored 1 point if the participant responded to them in the affirmative and zero if otherwise. Score < 2 was regarded as poor practice, 3–4 as fair while greater than 4 as good. The questions in sections 3 and 4 were included to make the assessment of CVD knowledge more stringent and rigorous since the participants, being healthcare professionals, might find the HDFQ easier than the lay public whom it was originally designed for.

Statistical analysis

Data was analysed with SPSS software version 21.0. Numerical data was expressed as mean (SD) while categorical data was expressed as percentages. Chi-square test was used to compare proportions. A p value < 0.05 indicated statistical significance.

Results

General characteristics of the subjects

The mean age of the study population was 41.7 (± 11.2) years while 87 (51.8%) were males. The median number of years of practice was 9.0 (3.0–15.0) years with 53 (31.5%) having various postgraduate qualifications. Majority 87 (51.7%) had their practices located in the urban areas. One hundred and fifty-six (92.8%) saw at least 10 hypertensives monthly in their practices while 144 (85.7%) and 85 (50.6%) saw a minimum of 10 diabetics and smokers respectively every month in their practices. The rest of their general characteristics is shown in Table 1.
Table 1
General characteristics of respondents
Variable
Frequency (%)
Age of respondents (years)
 ≤ 30
36 (21.4)
 31–45
71 (42.3)
 46–60
51 (30.4)
 > 60
10 (6.0)
Mean (± SD)
 41.73 (± 11.2) years
 
Gender
 Male
87 (51.8)
 Female
81 (48.2)
Marital status
 Single
37 (22.0)
 Married
131 (78.0)
Additional qualification
 None
115 (68.5)
 MSc
20 (11.9)
 Diploma/Cert
14 (8.3)
 Others
19 (11.3)
Number of years of practice
 ≤ 5
64 (38.1)
 6–10
35 (20.8)
 > 10
69 (41.1)
 Median (Q1, Q3)
9.0 (3.0, 15.0)
Location of practice
 Urban
86 (51.2)
 Semi/urban
73 (43.4)
 Rural
9 (5.4)
Average number of hypertensives seen per month
 < 10
12 (7.1)
 10–20
44 (26.2)
 > 20
112 (66.7)
Average number of diabetics seen per month
 <10
24 (14.3)
 11–20
72 (42.9)
 > 20
72 (42.9)
Number of smokers seen per month
 <10
83 (49.4)
 10–20
62 (36.9)
 > 20
23 (13.7)

Knowledge of CVD risk factors

Stroke was correctly identified as an example of a CVD by 73 (47.4%) of the respondents while the same number of respondents wrongly identified hypertension as a CVD. On the other hand 136 (81.4%) of the pharmacists correctly identified smoking as a CVD risk factor. Table 2 shows the number of the participants who correctly identified the diagnostic cut-off points for hypertension, diabetes, obesity with BMI, abdominal obesity and treatable dyslipidaemia.
Table 2
Knowledge of diagnostic cut-off for common CVD risk factors
Risk factor
Cut-off
Frequency (%)
Hypertension
aBP ≥ 140/90 mmHg
97 (57.7)
BP > 130/95 mmHg
19 (11.3)
BP > 120/80 mmHg
37 (22.0)
BP > 150/90 mmHg
1 (0.6)
Unknown
14 (8.3)
Diabetes
aFBS ≥ 126 mg/dl
53 (31.5)
FBS > 140 mg/dl
23 (13.7)
FBS > 110 mg/dl
67 (39.9)
Unknown
25 (14.9)
Obesity
aBMI ≥ 30 kg/m2
43 (25.6)
BMI > 35 kg/m2
32 (19.0)
BMI > 25 kg/m2
52 (31.0)
Unknown
41 (24.4)
Abdominal obesity (male)
aWC > 102 cm
38 (22.6)
> 88 cm
14 (8.3)
> 90 cm
32 (19.0)
Unknown
84 (50.0)
Abdominal obesity (female)
> 102 cm
20 (11.9)
a> 88 cm
43 (25.6)
> 90 cm
17 (10.1)
Unknown
88 (52.4)
Hypercholesterolaemia
aTc ≥ 240 mg/dl
22 (13.1)
Tc 220 mg/dl
18 (10.7)
Tc 200 mg/dl
37 (22.0)
Tc 190 mg/dl
15 (8.9)
Unknown
76 (45.2)
BP blood pressure, FBG fasting blood glucose, BMI Body Mass Index, WC waist circumference, Tc total cholesterol
aCorrect answer

Assessment of knowledge of CVD risk factors

Figure 1 shows the frequency scores of the HDFQ while Table 3 shows the responses of the participants to the items on the HDFQ. About 95.5% of the participants could identify the traditional risk factors for CVD viz hypertension (97.6%), smoking (97%), dyslipidaemia (97%), obesity (96.4%), physical inactivity (95.2%) and diabetes (91.7%), indicating high knowledge. They were also very knowledgeable of the impact of managing/controlling these risk factors in the development of heart disease and the relationship between diabetes and other CVD risk factors as they affect the risk of development of heart disease. However, participants displayed low knowledge of level High Density Lipoprotein cholesterol (HDL-c) in diabetes and females with diabetes having a higher risk of development of heart disease. Table 4 shows the association between the HDFQ scores and some of the socio-demographic characteristics of the participants. There was no relationship between age, gender, location of practice, duration of practice, possession of additional qualifications with HDFQ scores. Figure 2 shows the linear relationship between the HDFQ scores and knowledge of the diagnostic cut-offs for the CVD risk factors. The higher the HDFQ scores the more likely the pharmacists would correctly identify the diagnostic cut off (p = 0.045).
Table 3
Correct responses to HDFQ questionnaire
Questions
Frequency (%)
A person always knows when they have heart disease
142 (84.5)
If someone has a family history of heart disease, he/she is at risk for developing heart disease
157 (93.5)
The older a person is, the greater their risk of having heart disease
151 (89.9)
Smoking is a risk factor for heart disease
163 (97.0)
A person who stops smoking will lower their risk of heart disease
159 (94.6)
High blood pressure is a risk factor for heart disease
164 (97.6)
Keeping blood pressure under control will reduce a person’s risk for developing heart disease
162 (96.4)
High cholesterol is a risk factor for developing heart disease
163 (97.0)
Eating fatty foods does not affect blood cholesterol
157 (93.5)
If someone’s good cholesterol (HDL) is high he/she is at risk for heart disease
138 (82.1)
If someone’s bad cholesterol (LDL) is high he/she is at risk for heart disease
155 (92.3)
Being overweight increases a person’s risk for heart disease
162 (96.4)
Regular physical activity will lower a person’s chance of getting heart disease
160 (95.2)
Only exercising at a gym or in an exercise class will lower a person’s chance of developing heart disease
146 (86.9)
Walking and gardening are considered exercise that will help lower a person’s chance of developing heart disease
140 (83.3)
Diabetes is a risk factor for developing heart disease
154 (91.7)
High blood sugar puts a strain on the heart
131 (78.0)
If someone’s blood sugar is high over several months it can cause his/her cholesterol level to go up and increase his/her risk of heart disease
108 (64.3)
A person who has diabetes can reduce his/her risk of developing heart disease if he/she keeps his/her blood sugar level under control
153 (91.1)
Person with diabetes rarely have high cholesterol
130 (77.4)
If a person has diabetes, keeping his/her cholesterol under control will help lower his/her chance of having heart disease
145 (86.3)
People with diabetes tend to have low HDL (good) cholesterol
49 (29.2)
A person who has diabetes can reduce his/her risk of developing heart disease if he/she keeps his/her blood pressure under control
150 (89.3)
A person who has diabetes can reduce his/her risk of developing heart disease if he/she keeps his/her weight under control
153 (91.1)
Men with diabetes have a higher risk of heart disease than women with diabetes
37 (22.0)
Table 4
Association between HDFQ score category and socio-demographic characteristics
Characteristics
HDFQ score category
X2
p value
> 70
≤ 70
Age of respondents (years)
  
2.184
0.534
≤ 30
31 (86.1)
5 (13.9)
  
31–45
67 (94.4)
4 (5.6)
  
46–60
47 (92.2)
4 (7.8)
  
> 60
9 (90.0)
1 (10.0)
  
Gender
  
0.176
0.675
Male
79 (90.9)
8 (9.2)
  
Female
75 (92.6)
6 (7.4)
  
Marital status
  
0.003
0.955
Single
34 (91.9)
3 (8.1)
  
Married
120 (91.6)
11 (8.4)
  
Additional qualification
  
1.127
0.771
None
107 (93.0)
8 (7.0)
  
MSc
18 (90.0)
2 (10.0)
  
Diploma/Cert
12 (85.7)
2 (14.3)
  
Others
17 (89.5)
2 (10.0)
  
Number of years of practice
  
1.111
0.574
≤ 5
58 (90.6)
6 (9.4)
  
6–10
31 (88.6)
4 (11.4)
  
> 10
65 (94.2)
4 (5.8)
  
Median (Q1, Q3)
9.0 (3.0, 15.3)
6.0 (1.8, 14.8)
  
Location of practice
  
5.096
0.078
Urban
82 (95.3)
4 (4.7)
  
Semi/urban
63 (86.3)
10 (13.7)
  
Rural
8 (100.0)
0 (0.0)
  

Practice of primary prevention of CVD

One hundred and sixty of the pharmacists (95.2%) indicated that they had functional sphygmomanometers while 139 (82.7%) routinely measured the blood pressure of most clients who consulted them for a broad range of reasons. Details of pharmacists’ practice of primary prevention of CVD are shown in Table 5. With regards to knowledge of any guidelines for hypertension 73 (43.4%) were aware of the existence of guidelines on hypertension but none was able to mention any including the JNC VII guideline, which was the operational hypertension guideline in Nigeria as at the time of this study. Figure 3 the shows frequency of the scores on the practice of primary prevention of CVD. Eighty-one (48.2%) of them had good primary CVD prevention practice score. Table 6 shows an association between the HDFQ scores and practice of primary prevention of CVD. Those with HDFQ scores greater than 70% had higher primary CVD prevention scores (p = 0.026).
Table 5
Practice Primary Prevention of CVD among the Respondents
Practice
Frequency
Percentage
Availability Functional BP Sphygmomanometers
160
95.2
Routinely measure the BP of hypertensive client
139
82.7
Functional glucometer to measure blood glucose
122
72.6
Routinely measure BMI/waist circumference
48
28.6
Awareness of guideline on hypertension
73
43.5
Frequency of informing hypertensives or diabetics to check their cholesterol level
Very often
84
50.0
Sometimes
54
32.1
Rarely
20
11.9
Never
10
6.0
Frequency of advising hypertensives or diabetics on lifestyle management
Very often
116
69.0
Sometimes
38
22.6
Rarely
4
2.4
Never
10
6.0
Table 6
Association between HDFQ score grade and primary prevention practices
Primary prevention practice
HDFQ Score grade
X2
p-value
> 70
≤ 70
Poor
38 (82.6)
8 (17.3)
7.269
0.026*
Fair
38 (92.7)
3 (7.3)
Good
78 (93.3)
3 (3.7)
*Significant

Discussion

This study, first of its kind in Nigeria (to the best knowledge of the authors), shows that Community Pharmacists in Lagos, Nigeria have very good knowledge of CVD risk factors using the HDFQ instrument. This contrasts with the findings from a similar study done amongst staff members of a tertiary institution in South West Nigeria where 19.9% of the participants had good knowledge of CVD risk factors [24]. Wagner et al. [23], using the same instrument, also demonstrated low knowledge of CVD risk in a population of Spanish speaking diabetics in Puerto Rico. The higher level of knowledge observed in our study was not surprising since the studied population comprised healthcare professionals who should be knowledgeable about CVD. In our study the knowledge of these risk factors was independent of age, gender, location of practice, duration of practice and possession of additional qualifications and corroborates findings from similar studies [23, 24]. This high level of knowledge displayed by the participants in this study may provide a basis for a feasibility study on the effectiveness of Community Pharmacists in CVD risk factor screening in Nigeria.
Our study further demonstrated that the participants displayed good knowledge of both the behavioural (physical inactivity, smoking and unhealthy diets) and biologic (hypertension, diabetes, obesity and dyslipidaemia) risk factors for CVD. However in relative terms knowledge of diabetes and measures of obesity was lower. This was reflected in the lower of number of participants who correctly identified the diagnostic cut-offs for diabetes and abdominal obesity compared to hypertension and also the lower number of participants who screened clients for diabetes and obesity in their practices compared to hypertension. The reason for this might be might be due to the higher prevalence of hypertension compared to diabetes in the general Nigerian population [6, 8]. Secondly the invasive nature of screening for diabetes with a glucometer could be a demotivation for them and their clients. For obesity the technicalities for measuring parameters for obesity (waist circumference and body mass index) accurately may be exerting on the pharmacists in addition to time and space constraints. These may discourage them from screening for obesity. A similar study in Australia found availability of space a determinant of screening for obesity [25].
Our study also found that majority of the pharmacists were involved in primary prevention of CVD through screening for risk factors and counselling on the importance of healthy lifestyle choices. Hypertension screening was more commonly done than for diabetes and obesity. This might also be explained by the reasons adduced above. Joyce et al. [25], studying the practice of primary prevention of CVD among Community Pharmacists in Australia, found that hypertension was the most commonly screened risk factor, similar to what our study demonstrated.
Studies from various parts of the world have documented the feasibility of using Community Pharmacists in CVD screening in their practices [2628]. These screening programmes were mostly opportunistic in nature and involved both healthy and ill individuals. This feasibility compares well with studies that have demonstrated the feasibility of CVD screening by other health professionals [29, 30]. Some of these screening efforts reported prevalence of CVD risk factors similar to national prevalence and were also able to detect previously undiagnosed risk factors [28, 31]. Rohla et al. [31], in a cross-sectional study involving 184 pharmacies in Lower Austria, found an overall prevalence of CVD risk factors similar to reported prevalence in national surveys with about 30% of the cases being newly diagnosed. In addition public uptake of these screening programmes was positive [32, 33]. Furthermore in some of these studies identified cases were referred to the physicians for further evaluation and definitive management suggesting possible opportunities for a collaborative care model involving the physicians and the pharmacists [28, 31]. In summary, these studies demonstrate that CVD screening by Community Pharmacists is feasible, accessible and acceptable to the public and might be an effective alternative to public screening.
The success recorded above may be attributable to a host of factors. First, Community Pharmacists are located within the community and thus are usually the first point of contact and in some cases the only point of contact for patients seeking the services of a health-care provider without an appointment [18, 34]. In addition, they have extended hours of service which further increases accessibility to care. Being community dwelling, they build informal and genial relationships with members of their host communities, engendering their trust and loyalty. This places them in a vintage position to implement primary prevention strategies for CVD and collaborate with the physician in ensuring continuity of care [18, 34]. In some settings healthcare delivery service by them appears relatively cheaper and more cost effective for the patient [34].
Despite these benefits, some factors have been identified that could potentially hinder the ability and effectiveness of Community Pharmacists in CVD screening. In climes where pharmacists have been involved in CVD screening some barriers have been identified that limit their effectiveness. These include time constraints, limited physical space to ensure privacy of the patients, need for further training, lack of regulatory policy, remuneration and reimbursement mechanisms and poor uptake of CVD screening services by the public [33, 3537]. In Nigeria government policy integrating Community Pharmacists fully into the nation’s healthcare delivery system is apparently lacking. They operate primarily as private commercial ventures offering pharmaceutical services that complement the government’s healthcare system. In the absence of a government policy, training and certifying them to render CVD care delivery remains impracticable. By extension the expected collaborative linkage between them and physicians will at best be weak as they would be seen to be offering these services outside the ambit of government policy. This could also affect the public’s confidence in the uptake of such services. Time management constraints, lack of space, lack of training and lack of reimbursements might be potential impediments as in other climes. Most community pharmacies in Nigeria are sole proprietorships, driven by profit. Introduction of CVD care delivery services that will involve personal training to improve competencies, time and physical space resources and which are not recognised by the government nor covered by any reimbursement schemes of the National Health Insurance Program and which the patients may be unwilling to pay for might not be commercially appealing to them and may likely discourage them from venturing into such. Further, there is the issue of perceived ‘turf encroachment’, whereby pharmacists are perceived or act to supplant the role of physicians and compete rather than collaborate with them. This has been reported as another major impediment to the incorporation of pharmacists in mainstream CVD care [18]. In Nigeria, inter-professional rivalry in the health sector is rife, leading to frequent industrial disharmony and friction between the other health workers on one hand and the physicians on the other hand. The issue of ‘turf encroachment’ will be a major consideration in any collaborative healthcare delivery model that will involve the physician and the pharmacist as the latter might rightly or otherwise be seen to usurp or compete rather collaborate with the former. Issues such as ‘ownership of patients’ and remuneration structure might be potential sources of conflicts should this collaboration become operational. This scenario would be made worse in the absence of a government policy and operational guidelines. These are serious issues that may hinder the effectiveness of these health professionals in CVD screening services.

Limitations

This study has some limitations. The HDFQ used in this study was designed for assessment of knowledge of CVD risk factors in the lay public. Our study population comprised Community Pharmacists who are highly trained healthcare professionals. Thus results from the HDFQ are subject to bias. Secondly some of the questions involved self-report, which could have also introduced recall bias. The size of the population studied was small and this might have affected the results and the conclusions.

Conclusions

Our study has shown that Community Pharmacists in Nigeria have very good knowledge of CVD risk factors and also practice primary prevention of CVD. Thus assessment of the feasibility of using them for CVD risk factor screening is possible if enabling factors are in place. However, their knowledge of diabetes and obesity needs to be deepened. For them to be effective in the provision of these screening services there should a government policy that will regulate their training, certification, practice for CVD screening and as well as provide a framework of incentivising this service.

Conflicts of interest

None.

Unsere Produktempfehlungen

e.Dent – Das Online-Abo der Zahnmedizin

Online-Abonnement

Mit e.Dent erhalten Sie Zugang zu allen zahnmedizinischen Fortbildungen und unseren zahnmedizinischen und ausgesuchten medizinischen Zeitschriften.

e.Med Interdisziplinär

Kombi-Abonnement

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Literatur
1.
Zurück zum Zitat World Health Organization. Prevention of cardiovascular disease: guidelines for assessment and management of cardiovascular risk. Geneva, Switzerland; 2007. Accessed 22 July 2015. World Health Organization. Prevention of cardiovascular disease: guidelines for assessment and management of cardiovascular risk. Geneva, Switzerland; 2007. Accessed 22 July 2015.
2.
Zurück zum Zitat Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006;367(9524):1747–57.CrossRef Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006;367(9524):1747–57.CrossRef
3.
Zurück zum Zitat Bygbjerg IC. Double burden of non-communicable and infectious diseases in developing countries. Science. 2012;337(6101):1499–501.CrossRef Bygbjerg IC. Double burden of non-communicable and infectious diseases in developing countries. Science. 2012;337(6101):1499–501.CrossRef
4.
Zurück zum Zitat Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part II. Variation in cardiovascular diseases by specific ethnic groups and geographic regions and preventive strategies. Circulation. 2001;104(23):2855–64.CrossRef Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part II. Variation in cardiovascular diseases by specific ethnic groups and geographic regions and preventive strategies. Circulation. 2001;104(23):2855–64.CrossRef
5.
Zurück zum Zitat Steyn K, Sliwa K, Hawken S, Commerford P, Onen C. Risk factors associated with myocardial infarction in Africa: the INTERHEART Africa Study. Circulation. 2005;112:3554–61.CrossRef Steyn K, Sliwa K, Hawken S, Commerford P, Onen C. Risk factors associated with myocardial infarction in Africa: the INTERHEART Africa Study. Circulation. 2005;112:3554–61.CrossRef
6.
Zurück zum Zitat Adeloye D, Basquill C, Aderemi AV, et al. An estimate of the prevalence of hypertension in Nigeria: a systematic review and meta-analysis. J Hypertens. 2015;33(2):230–42.CrossRef Adeloye D, Basquill C, Aderemi AV, et al. An estimate of the prevalence of hypertension in Nigeria: a systematic review and meta-analysis. J Hypertens. 2015;33(2):230–42.CrossRef
8.
Zurück zum Zitat Ogbera OA, Ekpebegh C. Diabetes mellitus in Nigeria: the past, present and future. World J Diabetes. 2014;5(6):905–11.CrossRef Ogbera OA, Ekpebegh C. Diabetes mellitus in Nigeria: the past, present and future. World J Diabetes. 2014;5(6):905–11.CrossRef
9.
Zurück zum Zitat Odeyemi KA, Osibogun A, Akinsele AO, Sadiq L. The prevalence and predictors of cigarette smoking in secondary students in Nigeria. Niger Postgrad Med J. 2009;16:40–5.PubMed Odeyemi KA, Osibogun A, Akinsele AO, Sadiq L. The prevalence and predictors of cigarette smoking in secondary students in Nigeria. Niger Postgrad Med J. 2009;16:40–5.PubMed
10.
Zurück zum Zitat Akaralo-Anthony SN, Adebamowo CA. Prevalence and correlates of leisure-time physical activity among Nigerians. BMC Public Health. 2014;14:529.CrossRef Akaralo-Anthony SN, Adebamowo CA. Prevalence and correlates of leisure-time physical activity among Nigerians. BMC Public Health. 2014;14:529.CrossRef
12.
Zurück zum Zitat Ogundamola OJ, Oladosun OY. Pattern and outcomes of admissions in the medical wards of a tertiary health centre in a rural community of Ekiti State, Nigeria. Ann Afr Med. 2014;13:195–203.CrossRef Ogundamola OJ, Oladosun OY. Pattern and outcomes of admissions in the medical wards of a tertiary health centre in a rural community of Ekiti State, Nigeria. Ann Afr Med. 2014;13:195–203.CrossRef
13.
Zurück zum Zitat Oguanobi NI, Ejim EC, Onwubere BJ, Ike SO, Anisiuba BC, Ikeh VO, Aneke EO. Pattern of cardiovascular disease amongst medical admissions in a regional teaching hospital in South-eastern Nigeria. Niger J Cardiol. 2013;10:77–80.CrossRef Oguanobi NI, Ejim EC, Onwubere BJ, Ike SO, Anisiuba BC, Ikeh VO, Aneke EO. Pattern of cardiovascular disease amongst medical admissions in a regional teaching hospital in South-eastern Nigeria. Niger J Cardiol. 2013;10:77–80.CrossRef
14.
Zurück zum Zitat Schwappach D, Boluarte T, Suhrcke M. The economics of primary prevention of cardiovascular disease—a systematic review of economic evaluations. Cost Eff Resour Alloc. 2007;5(1):5.CrossRef Schwappach D, Boluarte T, Suhrcke M. The economics of primary prevention of cardiovascular disease—a systematic review of economic evaluations. Cost Eff Resour Alloc. 2007;5(1):5.CrossRef
15.
Zurück zum Zitat Ferdinand KC, Patterson KP, Taylor C, Fergus IV, Nasser SA. Community-based approaches to prevention and management of hypertension and cardiovascular disease. J Clin Hypertens (Greenwich). 2012;14:336–43.CrossRef Ferdinand KC, Patterson KP, Taylor C, Fergus IV, Nasser SA. Community-based approaches to prevention and management of hypertension and cardiovascular disease. J Clin Hypertens (Greenwich). 2012;14:336–43.CrossRef
16.
Zurück zum Zitat Machado M, Bajcar J, Guzzo GC, Einarson TR. Sensitivity of patient outcomes to pharmacist interventions. Part II: systematic review and meta-analysis in hypertension management. Ann Pharmacother. 2007;41(11):1770–81.CrossRef Machado M, Bajcar J, Guzzo GC, Einarson TR. Sensitivity of patient outcomes to pharmacist interventions. Part II: systematic review and meta-analysis in hypertension management. Ann Pharmacother. 2007;41(11):1770–81.CrossRef
17.
Zurück zum Zitat Blenkinsopp A, Anderson C, Armstrong M. Systematic review of the effectiveness of community pharmacy-based interventions to reduce risk behaviours and risk factors for coronary heart disease. J Public Health. 2003;25(2):144–53.CrossRef Blenkinsopp A, Anderson C, Armstrong M. Systematic review of the effectiveness of community pharmacy-based interventions to reduce risk behaviours and risk factors for coronary heart disease. J Public Health. 2003;25(2):144–53.CrossRef
18.
Zurück zum Zitat Morgado M, Rolo S, Castelo-Branco M. Pharmacist intervention to enhance hypertension control: a randomised controlled trial. Int J Clin Pharm. 2011;33(1):132–40.CrossRef Morgado M, Rolo S, Castelo-Branco M. Pharmacist intervention to enhance hypertension control: a randomised controlled trial. Int J Clin Pharm. 2011;33(1):132–40.CrossRef
19.
Zurück zum Zitat George J, McNamara GJ, Stewart K. The roles of community pharmacists in cardiovascular disease prevention and management. AMJ. 2011;4(5):266–72.CrossRef George J, McNamara GJ, Stewart K. The roles of community pharmacists in cardiovascular disease prevention and management. AMJ. 2011;4(5):266–72.CrossRef
20.
Zurück zum Zitat Santschi VS, Colosimo AL, Chilero A, Burnand B, Paradis G. Pharmacists interventions to improve cardiovascular risk factors in diabetes. a systematic review and meta-analysis. Diabetes Care. 2012;35:2706–17.CrossRef Santschi VS, Colosimo AL, Chilero A, Burnand B, Paradis G. Pharmacists interventions to improve cardiovascular risk factors in diabetes. a systematic review and meta-analysis. Diabetes Care. 2012;35:2706–17.CrossRef
21.
Zurück zum Zitat Araoye MO. Sample size determination. In: Research methodology with statistics for health and social sciences. 1st Ed. Ilorin: Nathadex Publishers; 2004. p. 115–20. Araoye MO. Sample size determination. In: Research methodology with statistics for health and social sciences. 1st Ed. Ilorin: Nathadex Publishers; 2004. p. 115–20.
22.
Zurück zum Zitat Wagner J, Lacey K, Chyun D, Abbot D. Development of a questionnaire to measure heart disease risk knowledge in people with diabetes. The Heart Disease Facts Questionnaire. Patient Educ Couns. 2005;58:82–7.CrossRef Wagner J, Lacey K, Chyun D, Abbot D. Development of a questionnaire to measure heart disease risk knowledge in people with diabetes. The Heart Disease Facts Questionnaire. Patient Educ Couns. 2005;58:82–7.CrossRef
23.
Zurück zum Zitat Wagner J, Lacey K, Chyun D, Abbot D. Knowledge of heart disease risks among Spanish speakers with diabetes. The role of interpreters in the medical encounter. Ethn Dis. 2005;15:679–84.PubMed Wagner J, Lacey K, Chyun D, Abbot D. Knowledge of heart disease risks among Spanish speakers with diabetes. The role of interpreters in the medical encounter. Ethn Dis. 2005;15:679–84.PubMed
24.
Zurück zum Zitat Akintunde AA, Akintunde TS, Opadijo OG. Knowledge of heart disease risk factors among workers in a Nigerian University. A call for concern. Niger Med J. 2015;56(2):91–5.CrossRef Akintunde AA, Akintunde TS, Opadijo OG. Knowledge of heart disease risk factors among workers in a Nigerian University. A call for concern. Niger Med J. 2015;56(2):91–5.CrossRef
25.
Zurück zum Zitat Joyce A, Berbatis C, Sunderland VB. Analysis of primary prevention services for cardiovascular disease in Australia’s community pharmacies. Aust N Z J Public Health. 2007;31:516–9.CrossRef Joyce A, Berbatis C, Sunderland VB. Analysis of primary prevention services for cardiovascular disease in Australia’s community pharmacies. Aust N Z J Public Health. 2007;31:516–9.CrossRef
26.
Zurück zum Zitat Jahangard-Rafsanjani Z, Hakimzadeh N, Sarayani A, Najafi S, Heidari K, Javadi MR, Hadjibabaie M, Gholami K. A community pharmacy-based cardiovascular risk screening service implemented in Iran. Pharm Pract. 2017;15(2):919–25.CrossRef Jahangard-Rafsanjani Z, Hakimzadeh N, Sarayani A, Najafi S, Heidari K, Javadi MR, Hadjibabaie M, Gholami K. A community pharmacy-based cardiovascular risk screening service implemented in Iran. Pharm Pract. 2017;15(2):919–25.CrossRef
27.
Zurück zum Zitat Via-Sosa MA, Toro C, Trave P, March MA. Screening premorbid metabolic syndrome in community pharmacies: a cross-sectional descriptive study. BMC Public Health. 2014;14:487.CrossRef Via-Sosa MA, Toro C, Trave P, March MA. Screening premorbid metabolic syndrome in community pharmacies: a cross-sectional descriptive study. BMC Public Health. 2014;14:487.CrossRef
28.
Zurück zum Zitat Willis A, Rivers P, Gray LJ, Davies M, Khunti K. The effectiveness of screening for diabetes and cardiovascular disease risk factors in a community pharmacy setting. PLoS ONE. 2014;9(4):e91157.CrossRef Willis A, Rivers P, Gray LJ, Davies M, Khunti K. The effectiveness of screening for diabetes and cardiovascular disease risk factors in a community pharmacy setting. PLoS ONE. 2014;9(4):e91157.CrossRef
29.
Zurück zum Zitat Horgan JMP, Blenkinsopp A, McManus RJ. Evaluation of cardiovascular opportunistic risk assessment pilot (‘Heart MOT’ service) in community pharmacies. J Public Health. 2010;32(1):110–6.CrossRef Horgan JMP, Blenkinsopp A, McManus RJ. Evaluation of cardiovascular opportunistic risk assessment pilot (‘Heart MOT’ service) in community pharmacies. J Public Health. 2010;32(1):110–6.CrossRef
30.
Zurück zum Zitat O’Donovan DO, Byre S, Sahm LJ. Pharmacists use of screening tools to estimate risk of CVD: a review of the literature. Pharmacy. 2014;2:27–39.CrossRef O’Donovan DO, Byre S, Sahm LJ. Pharmacists use of screening tools to estimate risk of CVD: a review of the literature. Pharmacy. 2014;2:27–39.CrossRef
31.
Zurück zum Zitat Rohla M, Haberfeld H, Sinzinger H, et al. Systematic screening for cardiovascular risk in pharmacies. Open Heart. 2016;3:e000497.CrossRef Rohla M, Haberfeld H, Sinzinger H, et al. Systematic screening for cardiovascular risk in pharmacies. Open Heart. 2016;3:e000497.CrossRef
32.
Zurück zum Zitat Taylor J, Krska J, Mackridge A. A community pharmacy-based cardio-vascular screening service: views of service users and the public. Int J Pharm Pract. 2012;20:277–84.CrossRef Taylor J, Krska J, Mackridge A. A community pharmacy-based cardio-vascular screening service: views of service users and the public. Int J Pharm Pract. 2012;20:277–84.CrossRef
33.
Zurück zum Zitat Hindi AMK, Schafheutle EI, Jacobs S. Patients and public perspectives of community pharmacies in the UK: a systematic review. Health Expect. 2018;21:409–28.CrossRef Hindi AMK, Schafheutle EI, Jacobs S. Patients and public perspectives of community pharmacies in the UK: a systematic review. Health Expect. 2018;21:409–28.CrossRef
34.
Zurück zum Zitat Chiazor EI, Evans M, van Worden H, Oparah AC. A systematic review of community pharmacists’ interventions in reducing major risk factors for cardiovascular disease. J Value Health Reg Issues. 2015;7c:9–21.CrossRef Chiazor EI, Evans M, van Worden H, Oparah AC. A systematic review of community pharmacists’ interventions in reducing major risk factors for cardiovascular disease. J Value Health Reg Issues. 2015;7c:9–21.CrossRef
35.
Zurück zum Zitat Jahangard-Rafsanjani Z, Sarayani A, Javadi MR, Hadjibabaie M, Rashidian A, Ahmadvand A, et al. Pharmacists’ attitudes and perceived barriers about community pharmacy-based cardiovascular risk screening services. J Pharm Care. 2014;2(4):142–8. Jahangard-Rafsanjani Z, Sarayani A, Javadi MR, Hadjibabaie M, Rashidian A, Ahmadvand A, et al. Pharmacists’ attitudes and perceived barriers about community pharmacy-based cardiovascular risk screening services. J Pharm Care. 2014;2(4):142–8.
36.
Zurück zum Zitat Kotecki JE, Elanjian SI, Torabi MR. Health promotion beliefs and practices amongst pharmacists. J Am Pharm Asso. 2000;40:773–9. Kotecki JE, Elanjian SI, Torabi MR. Health promotion beliefs and practices amongst pharmacists. J Am Pharm Asso. 2000;40:773–9.
37.
Zurück zum Zitat Uema SA, Vega EM, Armando PD, Fontana D. Barriers to pharmaceutical care in Argentina. Pharm World Sci. 2008;30:211–5.CrossRef Uema SA, Vega EM, Armando PD, Fontana D. Barriers to pharmaceutical care in Argentina. Pharm World Sci. 2008;30:211–5.CrossRef
Metadaten
Titel
Knowledge of cardiovascular disease risk factors and practice of primary prevention of cardiovascular disease by Community Pharmacists in Nigeria: a cross-sectional study
verfasst von
Casmir E. Amadi
Folasade O. Lawal
Amam C. Mbakwem
Jayne N. Ajuluchukwu
David A. Oke
Publikationsdatum
01.12.2018
Verlag
Springer International Publishing
Erschienen in
International Journal of Clinical Pharmacy / Ausgabe 6/2018
Print ISSN: 2210-7703
Elektronische ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-018-0744-3

Weitere Artikel der Ausgabe 6/2018

International Journal of Clinical Pharmacy 6/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.